CN | EN

Countdown to 2018 CBIIC:

Main Conference
  • Registration

  • Opening Ceremony

  • Session I: Welcome Remarks by the Hosts

    Chair:SONG Ruilin,Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

  • Session I: Welcome Remarks by the Hosts

    Senior Official from Suzhou Government

    LIU Dianbo,Chairman of PhIRDA, President of Luye Life Sciences Group

  • Session II: Keynote Speeches

    Chair: FANG Laiying,Vice President of Chinese Hospital Association

  • Keynote Speech: Cell Therapy -- Pharmacological Intervention Enters a Third Era

    HE Wei,Professor,Vice Chairperson of CPPCC National Committee, Executive Vice Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party

  • Keynote Speech: Cancer Immunotherapy: The End of Beginning

    Speaker:CHEN Lieping, Professor of Immunobiology, Dermatology and Medical Oncology at the Yale School of Medicine, Co-Director of the Cancer Immunology Program at the Yale Cancer Center

  • Panel: Global Trends on Pharmaceutical Innovation R&D

    Moderator:WANG Xiaodong,Member of National Academy of Sciences, USA, Foreign Associate of Chinese Academy of Sciences, Founder of BeiGene, Ltd.

    Panelists:

    HE Wei,Professor, Vice Chairperson of CPPCC National Committee, Executive Vice Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party

    CHEN Lieping,Professor of Immunobiology, Dermatology and Medical Oncology at the Yale School of Medicine, Co-Director of the Cancer Immunology Program at the Yale Cancer Center

    JIANG Hualiang, Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Director of Shanghai Institute of Materia Medica at ChineseAcademy of Sciences

    JIANG Jiandong,2017-2018 Annual Chairman of PhIRDA,Director of Institute of Materia Medica at Chinese Academy of Medical Sciences

    Alex XU,Chief Scientist (Pharmaceutical and Toxicology) of Center for Drug Evaluation, National Medical Products Administration

  • Session III: Keynote Speeches

    Chair:JIANG Feng,Executive Vice President of China Association for Medical Devices Industry (CAMDI)

  • Keynote Speech: Launch of New HKEX Biotech Chapter

    Charles LI,Chief Executive of Hong Kong Exchanges and Clearing Limited

  • Keynote Speech: Commercial Insurance and the Development of Big Health Industry

    CHEN Dongsheng,Chairman & CEO of Taikang Insurance Group

  • Keynote Speech: The Vitality of Global and China Pharmaceutical Innovation

    Martin Dewhurst,Senior Partner of McKinsey's London Office, Leader of McKinsey’s Global Pharmaceutical and Medical Products Practice

  • Panel: Dialogue between Pharmaceutical Innovation and Investment

    Moderator:TIAN Yuan, Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee, Founding Partner of Yuanming Capital

    Panelists:

    Charles LI,Chief Executive of Hong Kong Exchanges and Clearing Limited

    CHEN Dongsheng,Chairman & CEO of Taikang Insurance Group

    CHEN Qiyu,2017-2018 Annual Chairman of PhIRDA, Chairman of Fosun Pharma

    REN Jinsheng, Vice President of PhIRDA, Chairman of Simcere Pharmaceutical Group

    CAI Dajian,Vice-Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee, Founder & Chairman of GTJA Investment Group

    Houston HUANG,Head of China Global Investment Banking, J.P. Morgan

    Martin Dewhurst,Senior Partner of McKinsey's London Office, Leader of McKinsey’s Global Pharmaceutical and Medical Products Practice

  • Clinical-Trial Data Release of Innovative Drugs (Main Conference)

  • Session 1

    1st Half Moderator: DING Lieming,Chairman & CEO,Betta Pharmaceuticals Co., Ltd.

  • Project 1

    The First-in-Class New Drug for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Showed Clinically Highly Significant Efficacy

    CHU Kai-Min,Chairman & CEO, SINEW Pharma Inc.

  • Project 2

    Review of key phase I studies of chlorogenic acid for injection in GBM and prospects for phase II/III clinical trials.

    LI Wenbin, Director of Comprehensive Treatment Ward of Neuro-Oncology

  • Project 3

    Clinical study on Anlotinib Hydrochloride in the treatment of soft tissue sarcoma

    YAO Yang,Director of Department of Oncology, Shanghai Sixth People's Hospital

  • Project 4

    Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL inhibitor in the Tyrosine Kinase inhibitor - Resistant Patients with Chronic Myelogenous Leukemia: Preliminary Results of Phase I study

    YANG Dajun,Chairman & CEO, Ascentage Pharma

  • Session 2

    2st Half Moderator:Tan Lingshi,Chairman of PhIRDA Innovation R&D Services Specialty Committee, Chairman & CEO of dMed Biopharmaceutical Co., Ltd.

  • Project 5

    Phase III Clinical Trial Data Summary of HLX01 Rituximab Injection

    SHI Yuankai,Vice President, Cancer Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College

  • Project 6

    A first-in-class small molecule adminstered through hepatic artery for the treatment of hepatocellular carcinoma ( Phase I and IIa clinical trials)

    SHI Haikun,Chief medical officer, Teclison limited

  • Project 7

    Halneuron - Revolutionary Relief for Pain

    Christopher Gallen,CEO, WEX Pharmaceuticals Inc.

  • Project 8

    Phase I and Ⅱa Clinical Trials Results of ACC007,the Third Generation of NNRTI for HIV

    Chris SHENG,Vice President, Jiangsu Aidea Pharmaceutical Co., Ltd.